In conclusion, our findings in the LN229 and primary GBM cells support a new approach for the therapy of brain tumors by targeting NMDAR-mediated Top2β-induced DSBs, which are required for regulating transcription. The gene discussed is TOP2B; the disease is glioblastoma.